Kiniksa Pharmaceuticals Enters Material Definitive Agreement

TL;DR

Kiniksa just signed a big deal, filing an 8-K today.

AI Summary

Kiniksa Pharmaceuticals, Ltd. announced on June 25, 2024, that it has entered into a material definitive agreement. The company, incorporated in Bermuda with its principal executive offices in Hamilton, is involved in the pharmaceutical preparations industry.

Why It Matters

This filing indicates a significant new contract or partnership for Kiniksa Pharmaceuticals, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can carry inherent risks related to the terms, counterparty, and execution of the agreement.

Key Numbers

• 001-730430 — Commission File Number (Identifier for Kiniksa Pharmaceuticals, Ltd.)
• 98-1327726 — I.R.S. Employer Identification No. (Tax identification number for Kiniksa Pharmaceuticals, Ltd.)

Key Players & Entities

• Kiniksa Pharmaceuticals, Ltd. (company) — Registrant
• June 25, 2024 (date) — Date of earliest event reported
• Bermuda (location) — State or other jurisdiction of incorporation or organization
• Hamilton (location) — City of principal executive offices

FAQ

Key Financial Figures

• $0.000273235 — ich registered Class A Common Shares $0.000273235 par value KNSA The Nasdaq Stock Mar

Filing Documents

• tm2417478d1_8k.htm (8-K) — 28KB
• 0001104659-24-074763.txt ( ) — 198KB
• knsa-20240625.xsd (EX-101.SCH) — 3KB
• knsa-20240625_lab.xml (EX-101.LAB) — 33KB
• knsa-20240625_pre.xml (EX-101.PRE) — 22KB
• tm2417478d1_8k_htm.xml (XML) — 4KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement On June 25, 2024, a wholly-owned subsidiary of Kiniksa Pharmaceuticals, Ltd. (the "Company") entered into a Master Services Agreement (the "MSA") and Product Specific Agreement (the "PSA" and, together with the MSA, the "Agreement") with Samsung Biologics Co., Ltd. ("Samsung") pursuant to which Samsung will perform technology transfer, process performance qualification, manufacturing and supply services for the supply of the Company's ARCALYST (rilonacept) drug substance (the "Product"). Under the PSA, the Company committed to purchase process performance qualification and pre-approval inspection batches of the Product, which may be used for regulatory submissions and, pending regulatory approval, commercial sale. In addition, the Company is obligated to purchase additional batches of the Product in the five-year period of 2027 through 2031. The PSA will continue until the later of December 31, 2031 or the completion of the services thereunder, unless the PSA is terminated earlier. Prior to the expiration of the PSA, the parties have agreed to use commercially reasonable efforts to negotiate in good faith and enter into a new PSA that would govern future manufacturing and supply services for the Product. The MSA will have an initial term of ten (10) years and shall automatically renew for terms of two (2) years each unless either party gives the other party written notice of termination at least eighteen (18) months prior to the end of the then-current MSA term, provided that the MSA will remain in effect for so long as any product specific agreement is in effect. Either party may terminate the MSA or PSA in the event of a material breach by the other party that is not cured within 30 days' written notice or in the event of insolvency. The parties may also terminate the PSA if a force majeure event continues for more than 180 consecutive days and the parties are unable to negotiate a mutually satisfactory

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS, LTD. Date: June 25, 2024 By: /s/ Madelyn Zeylikman Madelyn Zeylikman Senior Vice President, General Counsel and Secretary